Cell-enhanced dissolution of carcinogenic lead chromate particles: the role of individual dissolution products in clastogenesis.
Lead chromate induces chromosomal damage as a result of extracellular dissolution producing solubilized chromium and lead and we show here that the dissolution process is greatly accelerated by the presence of cells. We have sought to determine which of these ions is involved in lead chromate-induced clastogenicity. Cell-mediated extracellular dissolution of particulate lead chromate resulted in the accumulation of both solubilized chromium and solubilized lead, reaching concentrations in the extracellular medium of 15 and 1.9 microM respectively and reaching concentrations inside the cell of 2700 and 97 microM respectively. Both the extracellular and intracellular accumulation of chromium was time dependent and both the solubilized lead and chromium increased proportionately from a lower dose to a higher dose. Exposing cells to water soluble sodium chromate under conditions which produced similar time-dependent intracellular concentrations of chromium also produced a similar amount and spectrum of chromosome damage as lead chromate. In contrast, exposure to lead glutamate resulted in intracellular lead levels 438-times higher than those produced by lead chromate, but produced no chromosome damage. A higher dose of lead glutamate was weakly clastogenic, but it induced a different spectrum of chromosomal aberrations than lead chromate. Pretreatment of cells with vitamin E had no effect on the uptake of chromium, but reduced both sodium chromate- and lead chromate-induced clastogenesis by 54-93%. Vitamin E pretreatment did not affect lead glutamate-induced clastogenesis. The results of this study indicate that although lead(II) is weakly clastogenic at high doses, hexavalent chromium is the proximate clastogen in lead chromate-induced clastogenesis. Additionally, this is the first report that pretreatment of cells with vitamin E can block clastogenesis induced by particulate chromates.
Wise
J P
JP
Department of Pharmacology, George Washington University Medical Center, Washington, DC 20037.
Stearns
D M
DM
Wetterhahn
K E
KE
Patierno
S R
SR
D000818:Animals; D016466:CHO Cells / Q000187:drug effects / Q000378:metabolism; D002840:Chromates / Q000493:pharmacokinetics* / Q000633:toxicity*; D002857:Chromium / Q000493:pharmacokinetics / Q000633:toxicity; D002875:Chromosomes / Q000187:drug effects; D006224:Cricetinae; D004347:Drug Interactions; D005971:Glutamates / Q000633:toxicity; D007424:Intracellular Fluid / Q000378:metabolism; D007854:Lead / Q000493:pharmacokinetics* / Q000633:toxicity*; D009153:Mutagens / Q000378:metabolism / Q000493:pharmacokinetics* / Q000633:toxicity*; D009374:Neoplasms, Experimental / Q000139:chemically induced / Q000517:prevention & control; D014810:Vitamin E / Q000627:therapeutic use
D002840:Chromates; D005971:Glutamates; D009153:Mutagens; D002857:Chromium; D014810:Vitamin E; D007854:Lead; C031895:lead chromate